Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers February 27, 2017
Pharmacy Choice - News - U.S. Pharmaceutical Industry - February 27, 2017

Pharmacy News

 U.S. Pharmaceutical Industry
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

2/26/17 - 5 Top NASDAQ Biotech Stocks: Bellerophon Therapeutics Gains 97 Percent
Last week s news was varied: from Roche reporting patient death in the phase 3 trial of the company s hemophilia blockbuster emicizumab, to Novartis cancer drug Zykadia being granted priority review by the US FDA. Bellerophon Therapeutics Vermillion, Inc. Galectin Therapeutics Jaguar Animal Health Alphatec Holdings Bellerophon Therapeutics
2/26/17 - Drug Pricing Lunacy by Kaleo Pharma
As America s opioid crisis reaches epidemic levels, Kaleo has jacked up the list price for its Evzio auto-injector by 600 percent, soaring from $690 several years ago to $4,500, according to lawmakers. And that, in a nutshell, illustrates the lunacy of the U.S. health care system. Our system of health care financing is the most cynical such s
2/26/17 - Insider Q&A: Allergan CEO on impact of limiting price hikes
As drugmakers pushed back against rising criticism over sky-high U.S. prescription drug prices, one pharmaceutical company went public with a pledge....
2/26/17 - Merck's Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in Bone Marrow Transplant Recipients, Highly Effective Through Week 24 Post-Transplant in Pivotal Phase 3 Study
Merck& Co., Inc., known as MSD outside the United States and Canada, today announced results of the pivotal Phase 3 clinical study of letermovir, an investigational antiviral medicine for the prevention of clinically-significant cytomegalovirus infection in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant, also.
2/26/17 - New Findings in FDA Actions Described from Massachusetts Eye and Ear Infirmary (Clinical Evidence Supporting US Food and Drug Administration Approval...
By a News Reporter-Staff News Editor at Medical Letter on the CDC& FDA Research findings on FDA Actions are discussed in a new report. We characterized the pivotal studies supporting FDA approval of otolaryngologic prescription drug indications. " Between 2005 and 2014, the FDA approved 48 otolaryngologic prescription drug indications based on 64
2/26/17 - Some cancer drugs do little more than frustrate patients
McCarthy said she's frustrated that the Food and Drug Administration is approving cancer drugs without proof that they cure patients or help them live longer. Pushed by patient advocates who want earlier access to medications, the- FDA has approved a flurry of oncology drugs in recent years, giving some people with cancer a renewed sense of hope an
2/25/17 - ADMA Biologics Reports Year End 2016 Financial Results, Accomplishments and Upcoming Milestones [Daily Tribune (Bahrain)]
-ADMA Biologics, Inc., a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention of certain infectious diseases, today announced its financial results for the year ended December 31, 2016. During the recently...
2/25/17 - Baebies Receives FDA de novo Clearance for First Lysosomal Storage Disease Newborn Screening Platform, SEEKER
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week- Baebies, a company focused on advancing newborn screening and pediatric testing, announced it has received de novo clearance from the U.S. Food and Drug Administration for SEEKER. "Although these LSDs have FDA approved therapies, this is a significant milestone for the LSD
2/25/17 - Drug firms want case moved to fed court
HUNTINGTON- Like they have done in other lawsuits against them, wholesale drug distributors accused by Huntington officials of flooding the city with an excess of prescription drugs are requesting the case be tried in federal court rather than a local court. Gregory Donald Chaney, AmerisourceBergen Drug Co., Cardinal Health Inc. and McKesson Corp.
2/25/17 - FDA Approves EMFLAZA? deflazacort Tablets and Oral Suspension for the Treatment of Duchenne Muscular Dystrophy in Patients 5 Years and Older
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week The FDA granted EMFLAZA priority review, which is reserved for investigational medicines that may offer major advances in treatment over existing options. "We are pleased to learn that the FDA has approved EMFLAZA," said Pat Furlong, founding President and CEO of Parent Proj
2/25/17 - FDA Issues Final Rule for New Animal Drugs for Use in Animal Feed
WASHINGTON, Feb. 25 The Food and Drug Administration published the following rule in the Federal Register for approval of New Animal Drug applications and withdrawal of approval of New Animal Drug Applications:. Where applicable, FDA is also withdrawing approval of those parts of the NADAs that pertain to use of these antimicrobial drugs for prod
2/25/17 - FDA Issues Rule for Withdrawal of Approval of New Animal Drug Application
WASHINGTON, Feb. 25 The Food and Drug Administration published the following rule in the Federal Register for withdrawal of Approval of a New Animal Drug Application:. Sujaya Dessai, Center for Veterinary Medicine, Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 240-402-5761, sujaya.dessai@fda.hhs.gov. Putney, Inc., One Monu
2/25/17 - Findings from University of Pennsylvania Hospital in the Area of Drug Delivery Systems Described (Erythrocytes as Carriers for Drug Delivery in Blood...
Findings from University of Pennsylvania Hospital in the Area of Drug Delivery Systems Described. According to news reporting out of Philadelphia, Pennsylvania, by NewsRx editors, research stated, "Red blood cells are innate carriers that can also be engineered to improve the pharmacokinetics and pharmacodynamics of many drugs, particularly...
2/25/17 - Fulcrum Therapeutics Strengthens its Board of Directors with the Addition of Alan Ezekowitz, MBChB, D.Phil., and James J. Collins, Ph.D.
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week Fulcrum Therapeutics, a company focused on discovering and developing small molecule therapies to unlock gene control and treat serious genetic diseases, announced the appointment of Alan Ezekowitz, MBChB, D.Phil., and James J. Collins, Ph.D., to its Board of Directors. Their
2/25/17 - Global Weight Loss and Obesity Management Market Forecast to 2024 New Report by Data Bridge Market Research
Global Weight Loss and Obesity Management Market, by Fitness Equipment (Cardiovascular Training Equipment, Strength Training Equipment, Body Composition Analyzers, Fitness Monitoring Equipment), by Surgical Equipment (Minimally Invasive Surgical Equipment, Non-Invasive Surgical Equipment), by Dietary Supplements, by Services, by Geography Indus
2/25/17 - Idera Pharmaceuticals Presents Update from Ongoing Phase 1 Dose Escalation Clinical Trial of Intratumoral IMO-2125 in Combination with Ipilimumab in Metastatic Melanoma Patients Refractory to Anti-PD-1 Treatment at the 2017 ASCO-SITC Clinical Immuno-
-Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today is reporting additional data from the dose-escalation phase of its ongoing Phase 1/ 2 clinical trial of intratumoral IMO-2125, an agonist of TLR9 in combination with ipilimumab
2/25/17 - IMPORTANT INVESTOR NOTICE: Lundin Law PC Announces Securities Class Action Lawsuit against TG Therapeutics, Inc. and Strongly Advises Investors with Losses to Contact the Firm
LOS ANGELES, CA/ ACCESSWIRE/ February 25, 2017/ Lundin Law PC, a shareholder rights firm, announces a class action lawsuit against TG Therapeutics, Inc.. Investors, who purchased or otherwise acquired TG Therapeutics shares between September 15, 2014 and October 12, 2016 inclusive, are encouraged to contact the firm 60 days within this notice, also
2/25/17 - Intellipharmaceutics Announces FDA Approval for 500 mg and 750 mg Generic Glucophage XR [T-break Tech (Middle East)]
Intellipharmaceutics International Inc., a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs announced that the Company today received final approval from the U.S. Food and Drug Administration for the Company`s abbreviated new drug...
2/25/17 - R.I. police find bonanza from Google settlement [The Providence Journal, R.I.]
Feb. 25 How did Rhode Island law enforcers spend $182,159,809 in settlement money? For their roles in exposing a shady marketing technique that allowed users of Google AdWords to illegally sell non- FDA- approved prescription drugs to American consumers, Rhode Island law-enforcement agencies reaped big rewards: $230 million to be distributed acro
2/25/17 - Robbins Arroyo LLP: Regulus Therapeutics Inc. RGLS Misled Shareholders According to a Recently Filed Class Action
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week Shareholder rights law firm Robbins Arroyo LLP announces that a class action complaint was filed against Regulus Therapeutics Inc. in the U.S. District Court for the Southern District of California. The complaint is brought on behalf of all purchasers of Regulus securities be
2/25/17 - SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Egalet Corporation of Class Action Lawsuit and Upcoming Deadline - EGLT
Pomerantz LLP announces that a class action lawsuit has been filed against Egalet Corporation and certain of its officers. The class action, filed in United States District Court, Eastern District of Pennsylvania, is on behalf of a class consisting of investors who purchased or otherwise acquired Egalet securities, seeking to recover compensable
2/25/17 - SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regulus Therapeutics Inc. of Class Action Lawsuit and...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Regulus Therapeutics Inc. of Class Action Lawsuit and Upcoming Deadline RGLS. By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week- Pomerantz LLP announces that a class action lawsuit has been filed against Regulus Therapeutics Inc.
2/25/17 - SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in TG Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline - TGTX
NEW YORK, NY/ ACCESSWIRE/ February 24, 2017/ Pomerantz LLP announces that a class action lawsuit has been filed against TG Therapeutics, Inc. and certain of its officers. The class action, filed in United States District Court, Southern District of New York, and docketed under 17- cv-00508, is on behalf of a class consisting of all persons or entit
2/25/17 - Sixty jobs created at West Lothian pharmaceutical company [Tehran Times (Iran)]
Sixty jobs are being created at a Bathgate- based pharmaceutical company. The Bathgate site was originally purpose-built as a clinical packaging and logistics facility and was officially opened by Quintiles in September 1997. Since then it has expanded significantly prior to becoming part of the Catalent network in 2007..
2/25/17 - The Right C Vitamin C Supplement Now Available on StackedNutrition.com [Syrian Arab News Agency]
-Doctor C LLC, a company based in Arizona known for its vitamin C supplement The Right C, announced that product will now be available for purchase on StackedNutrition.com, a popular health and nutritional products site. We are pleased to announce that The Right C is now available for sale on StackedNutrition.com, said Travis Lingenfelter, CEO of D
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415